Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast Cancer
暂无分享,去创建一个
G. Mills | G. Hortobagyi | K. Do | F. Meric-Bernstam | B. Hennessy | A. González-Angulo | B. Arun | J. Lanchbury | Shuying Liu | K. Timms | J. Litton | Huiqin Chen | K. Stemke‐Hale | J. Potter
[1] K. Gelmon,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2011 .
[2] J. Kwon,et al. Expanding the criteria for BRCA mutation testing in breast cancer survivors. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] G. Mills,et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] Mark Robson,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial , 2010, The Lancet.
[5] A. Tutt,et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial , 2010, The Lancet.
[6] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.
[7] M. Federico,et al. Favourable ten-year overall survival in a Caucasian population with high probability of hereditary breast cancer , 2010, BMC Cancer.
[8] A. Ashworth,et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.
[9] P. Goodwin,et al. Prognosis of BRCA-associated breast cancer: a summary of evidence , 2009, Breast Cancer Research and Treatment.
[10] Stephanie A Cohen,et al. The prevalence of BRCA1 mutations among young women with triple-negative breast cancer , 2009, BMC Cancer.
[11] Christopher I Amos,et al. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] Caroline Seynaeve,et al. Distant disease-free interval, site of first relapse and post-relapse survival in BRCA1- and BRCA2-associated compared to sporadic breast cancer patients , 2008, Breast Cancer Research and Treatment.
[13] S. Schnitt,et al. Prevalence of BRCA1 mutations in triple negative breast cancer (BC). , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[15] Alan Ashworth,et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.
[16] I. Bedrosian. The prognostic implication of the basal-like (cyclin Ehigh/ p27low/p53+glomeruloid-microvascular-proliferation +) phenotype of BRCA1-related breast cancer , 2005 .
[17] A. Ashworth,et al. Hallmarks of 'BRCAness' in sporadic cancers , 2004, Nature Reviews Cancer.
[18] William D. Foulkes,et al. Re: Germline BRCA1 Mutations and a Basal Epithelial Phenotype in Breast Cancer , 2004 .
[19] O. Olopade,et al. Estrogen Receptor Status in BRCA1- and BRCA2-Related Breast Cancer , 2004, Clinical Cancer Research.
[20] L. Bégin,et al. The Prognostic Implication of the Basal-Like (Cyclin Ehigh/p27low/p53+/Glomeruloid-Microvascular-Proliferation+) Phenotype of BRCA1-Related Breast Cancer , 2004, Cancer Research.
[21] L. Bégin,et al. Advances in Brief The Prognostic Implication of the Basal-Like ( Cyclin Ehigh / p 27 low / p 53 / Glomeruloid-Microvascular-Proliferation ) Phenotype of BRCA 1-Related Breast Cancer , 2004 .
[22] L. Bégin,et al. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. , 2004, Journal of the National Cancer Institute.
[23] R. Tibshirani,et al. Repeated observation of breast tumor subtypes in independent gene expression data sets , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[24] R. Tibshirani,et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[25] J. Sng,et al. Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] D. Birnbaum,et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. , 2000, Cancer research.
[27] L. Tsui,et al. A suggested nomenclature for designating mutations , 1993, Human mutation.